MUMBAI, India, and NAPLES, Fla., July 28, 2026
Lupin Limited has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes, further strengthening the company’s expanding portfolio of generic injectable medicines in the United States. Approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act), the product has been determined to be bioequivalent to the reference listed drug Valium® Injection from Hoffmann-La Roche. The newly approved formulation is indicated for the management of anxiety disorders and the short-term relief of anxiety symptoms, offering healthcare providers a ready-to-use injectable option designed to support efficient patient care. According to IQVIA data, the reference product recorded approximately USD 77.9 million in annual U.S. sales for the twelve months ending May 2026, highlighting a significant commercial opportunity for Lupin as it continues expanding its presence in the highly competitive U.S. generic pharmaceuticals market.
FDA Approval Strengthens Lupin’s Generic Injectables Portfolio
The latest FDA approval reinforces Lupin’s commitment to expanding access to high-quality, affordable generic medicines while strengthening its position in the U.S. healthcare market. Diazepam Injection USP is supplied in single-dose prefilled syringes, offering hospitals and healthcare professionals a convenient, ready-to-administer formulation that supports efficient medication preparation and minimizes handling before administration. The product has been approved as bioequivalent to Valium® Injection, ensuring comparable quality, safety, and therapeutic performance to the branded reference medicine. Diazepam is widely used for the treatment of anxiety disorders and for providing short-term relief of acute anxiety symptoms, making it an important therapy within hospital and emergency care settings. The approval further demonstrates Lupin’s continued success in developing complex generic products that address essential therapeutic needs while expanding treatment accessibility for patients across the United States.
Expanding U.S. Presence Through Regulatory Excellence
The approval of Diazepam Injection USP reflects Lupin’s strong regulatory capabilities and ongoing investment in developing complex injectable and specialty pharmaceutical products for global markets. Headquartered in Mumbai, India, Lupin operates across more than 100 countries, supplying a broad portfolio that includes generic medicines, branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company continues to build its leadership position in multiple therapeutic areas, including central nervous system disorders, respiratory diseases, cardiovascular medicine, anti-diabetic therapies, anti-infectives, gastrointestinal disorders, and women’s health. Supported by 15 advanced manufacturing facilities and seven global research centers, Lupin consistently focuses on delivering high-quality pharmaceutical products that meet stringent international regulatory standards while addressing evolving healthcare needs worldwide.
Advertisement
Affordable Medicines Continue Driving Global Healthcare Access
As healthcare systems increasingly prioritize cost-effective treatment options, the availability of FDA-approved generic medicines plays a vital role in improving patient access while helping reduce overall healthcare expenditure. Lupin’s Diazepam Injection USP adds another important product to the company’s growing injectable portfolio and reinforces its long-term strategy of providing reliable, affordable therapeutic alternatives across key disease areas. The approval also highlights the company’s continued investment in research, manufacturing excellence, and regulatory compliance, enabling faster introduction of high-demand generic medicines into the U.S. market. With a strong pipeline of complex generics and specialty pharmaceutical products, Lupin remains committed to advancing global healthcare by delivering innovative, high-quality medicines that improve treatment availability, support healthcare professionals, and contribute to better patient outcomes worldwide.
Source: Lupin press release
